- The introduction of direct-acting antivirals (DAAs) coincides with a decline in UK liver transplant (LT) waitlist rates for HCV-related cirrhosis and hepatocellular carcinoma (HCC).
Why this matters
- The study quantifies qualitative reports of declining HCV-related liver disease.
- The decline in HCC registrations further supports DAA safety.
- Study of UK adults awaiting LT during 2006-2017.
- Registrations after April 2014 were categorized as being in the DAA era, beginning with early-access programs.
- Funding: None disclosed.
- The proportion of patients waitlisted for HCV cirrhosis dropped after DAAs were introduced, from 10.5% in 2013 to 4.7% in 2016 (P<.001 style="list-style-type:circle;">
- UK model for end-stage liver disease (UKELD) remained stable (55), suggesting no change in the threshold used for waitlisting.
- Cirrhosis: no significant change in proportion who died, underwent transplant, or were delisted.
- HCC: significant decrease in 1-year mortality (2.9% vs 0.0%; P=.04); no change in number transplanted or delisted.
- Retrospective design.